Roop Dutta1, Sally Hurley2, David Atkins2, Joseph Weinstein2, John Wylie3. 1. St. Elizabeth's Medical Center, Boston, MA, USA. 2. Steward Medical Group, Dallas, TX, USA. 3. St. Elizabeth's Medical Center, Boston, MA, USA. john.wylie@steward.org.
Abstract
BACKGROUND: Anticoagulation is a cornerstone in atrial fibrillation (AF) management for stroke prevention. Studies showed that oral anticoagulants (OAC), previously limited to warfarin, were underused. Recently, non-vitamin K oral anticoagulants (NOACs) have seen widespread adoption, but it has not been well studied whether there has been a subsequent increase in OAC usage in AF patients. METHODS: We quantified OAC rates in AF patients in a large multispecialty health system in the Northeast United States. A total of 351,795 patients seen in the network over the preceding 18 months were reviewed. RESULTS: Of these patients, 8727 (2.5%) carried a diagnosis of AF, and, of the 6933 patients with a CHA2DS2-VASc score of 2 or higher, 5576 (80.4%) had an OAC listed as an active medication or had received a left atrial appendage occlusion device. Of the 6605 patients treated with an OAC, 5308 (80.4%) were treated with a NOAC and 1295 (19.6%) were prescribed warfarin. A higher percentage of patients with CHA2DS2-VASc ≥ 2 who had seen a cardiologist were treated with an OAC vs. those who had not seen a cardiologist in the prior 18 months (83.95% vs. 67.43%, p < 0.01). CONCLUSIONS: We show dramatically increased OAC usage among patients with AF and that NOACs comprise the large majority of OACs compared with previous studies. This suggests an association between widespread adoption of NOACs and increased oral anticoagulation rates. Future directions include assessing barriers to oral anticoagulation and developing interventions to reduce disparity in OAC use between clinics.
BACKGROUND: Anticoagulation is a cornerstone in atrial fibrillation (AF) management for stroke prevention. Studies showed that oral anticoagulants (OAC), previously limited to warfarin, were underused. Recently, non-vitamin K oral anticoagulants (NOACs) have seen widespread adoption, but it has not been well studied whether there has been a subsequent increase in OAC usage in AF patients. METHODS: We quantified OAC rates in AF patients in a large multispecialty health system in the Northeast United States. A total of 351,795 patients seen in the network over the preceding 18 months were reviewed. RESULTS: Of these patients, 8727 (2.5%) carried a diagnosis of AF, and, of the 6933 patients with a CHA2DS2-VASc score of 2 or higher, 5576 (80.4%) had an OAC listed as an active medication or had received a left atrial appendage occlusion device. Of the 6605 patients treated with an OAC, 5308 (80.4%) were treated with a NOAC and 1295 (19.6%) were prescribed warfarin. A higher percentage of patients with CHA2DS2-VASc ≥ 2 who had seen a cardiologist were treated with an OAC vs. those who had not seen a cardiologist in the prior 18 months (83.95% vs. 67.43%, p < 0.01). CONCLUSIONS: We show dramatically increased OAC usage among patients with AF and that NOACs comprise the large majority of OACs compared with previous studies. This suggests an association between widespread adoption of NOACs and increased oral anticoagulation rates. Future directions include assessing barriers to oral anticoagulation and developing interventions to reduce disparity in OAC use between clinics.
Authors: Paul A Heidenreich; N A Mark Estes; Gregg C Fonarow; Corrine Y Jurgens; Michelle M Kittleson; Joseph E Marine; David D McManus; Robert L McNamara Journal: J Am Coll Cardiol Date: 2020-12-07 Impact factor: 24.094
Authors: Craig T January; L Samuel Wann; Hugh Calkins; Lin Y Chen; Joaquin E Cigarroa; Joseph C Cleveland; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Karen L Furie; Paul A Heidenreich; Katherine T Murray; Julie B Shea; Cynthia M Tracy; Clyde W Yancy Journal: Circulation Date: 2019-01-28 Impact factor: 29.690
Authors: Gerald V Naccarelli; Mohammed Ruzieh; Deborah L Wolbrette; Mauricio Sendra-Ferrer; John van Harskamp; Barbara Bentz; Gregory Caputo; Nathan McConkey; Kevin Mills; Stephen Wasemiller; Jovan Plamenac; Douglas Leslie; Frendy D Glasser; Thomas W Abendroth Journal: Am J Med Date: 2020-12-24 Impact factor: 4.965
Authors: Susan Colilla; Ann Crow; William Petkun; Daniel E Singer; Teresa Simon; Xianchen Liu Journal: Am J Cardiol Date: 2013-07-04 Impact factor: 2.778
Authors: Lucas N Marzec; Jingyan Wang; Nilay D Shah; Paul S Chan; Henry H Ting; Kensey L Gosch; Jonathan C Hsu; Thomas M Maddox Journal: J Am Coll Cardiol Date: 2017-05-23 Impact factor: 24.094
Authors: Sean D Pokorney; Noelle Cocoros; Hussein R Al-Khalidi; Kevin Haynes; Shuang Li; Sana M Al-Khatib; Jacqueline Corrigan-Curay; Meighan Rogers Driscoll; Crystal Garcia; Sara B Calvert; Thomas Harkins; Robert Jin; Daniel Knecht; Mark Levenson; Nancy D Lin; David Martin; Debbe McCall; Cheryl McMahill-Walraven; Vinit Nair; Lauren Parlett; Andrew Petrone; Robert Temple; Rongmei Zhang; Yunping Zhou; Richard Platt; Christopher B Granger Journal: JAMA Netw Open Date: 2022-05-02
Authors: Dragos Vinereanu; Renato D Lopes; M Cecilia Bahit; Denis Xavier; Jie Jiang; Hussein R Al-Khalidi; Wensheng He; Ying Xian; Andrea O Ciobanu; Deepak Y Kamath; Kathleen A Fox; Meena P Rao; Sean D Pokorney; Otavio Berwanger; Carlos Tajer; Pedro G M de Barros E Silva; Mayme L Roettig; Yong Huo; Christopher B Granger Journal: Lancet Date: 2017-08-28 Impact factor: 79.321